124 related articles for article (PubMed ID: 28341308)
21. Intravenous immunoglobulins: evolution of commercial IVIG preparations.
Hooper JA
Immunol Allergy Clin North Am; 2008 Nov; 28(4):765-78, viii. PubMed ID: 18940573
[TBL] [Abstract][Full Text] [Related]
22. Peripheral immunoglobulin secreting cells in immunodeficiencies; effects of intravenous immune globulin.
Iseki M; Ank BJ; Stiehm ER
Ann Allergy; 1994 May; 72(5):419-24. PubMed ID: 8179228
[TBL] [Abstract][Full Text] [Related]
23. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
[TBL] [Abstract][Full Text] [Related]
24. [Therapy with immunoglobulins].
Müller E; Zabel P
Immun Infekt; 1990 Oct; 18(5):162-3. PubMed ID: 2265862
[TBL] [Abstract][Full Text] [Related]
25. Traces of pFc' in IVIG interact with human IgG Fc domains and counteract aggregation.
Rispens T; Himly M; Ooievaar-De Heer P; den Bleker TH; Aalberse RC
Eur J Pharm Sci; 2010 Apr; 40(1):62-8. PubMed ID: 20211252
[TBL] [Abstract][Full Text] [Related]
26. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
Psathas PA; Kuzmission A; Ikeda K; Yasuo S
Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
[TBL] [Abstract][Full Text] [Related]
27. IgG anti-IgA antibodies in paediatric antibody-deficient patients receiving intravenous immunoglobulin.
Torabi Sagvand B; Mirminachi B; Abolhassani H; Shokouhfar T; Keihanian T; Amirzargar A; Mahdaviani A; Aghamohammadi A
Allergol Immunopathol (Madr); 2015; 43(4):403-8. PubMed ID: 25201762
[TBL] [Abstract][Full Text] [Related]
28. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline.
Cramer M; Frei R; Sebald A; Mazzoletti P; Maeder W
Vox Sang; 2009 Apr; 96(3):219-25. PubMed ID: 19207169
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.
Rojavin MA; Hubsch A; Lawo JP
J Clin Immunol; 2016 Apr; 36(3):210-9. PubMed ID: 26910102
[TBL] [Abstract][Full Text] [Related]
30. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
[TBL] [Abstract][Full Text] [Related]
31. Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura.
Kane I; Ragucci D; Shatat IF; Bussel J; Kalpatthi R
Br J Haematol; 2010 Apr; 149(1):79-83. PubMed ID: 20096011
[TBL] [Abstract][Full Text] [Related]
32. Clinical uses of intravenous immune globulin.
Knapp MJ; Colburn PA
Clin Pharm; 1990 Jul; 9(7):509-29. PubMed ID: 2198124
[TBL] [Abstract][Full Text] [Related]
33. [Intravenous immunoglobulin therapy].
Mouthon L
Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
[TBL] [Abstract][Full Text] [Related]
34. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.
Bolli R; Woodtli K; Bärtschi M; Höfferer L; Lerch P
Biologicals; 2010 Jan; 38(1):150-7. PubMed ID: 19931468
[TBL] [Abstract][Full Text] [Related]
35. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.
Wasserman RL
Expert Rev Clin Immunol; 2014 Mar; 10(3):325-37. PubMed ID: 24527947
[TBL] [Abstract][Full Text] [Related]
36. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
37. [Contamination of IgG preparation for intravenous use with IgA. I. Development of ELISA tests for determination of low concentrations of IgAc, IgA1, IgA2, IgG and IgM].
Dovezenski N; Velicković Z; Tosić Lj; Nikolić G; Popović O; Romić M; Djokić M; Mijusković Z
Srp Arh Celok Lek; 1994; 122 Suppl 1():49-50. PubMed ID: 18173186
[TBL] [Abstract][Full Text] [Related]
38. Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity.
Vargas M; Segura Á; Wu YW; Herrera M; Chou ML; Villalta M; León G; Burnouf T
Vox Sang; 2015 Feb; 108(2):169-77. PubMed ID: 25469648
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
Jolles S; Sleasman JW
Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
[TBL] [Abstract][Full Text] [Related]
40. Solid-phase immunoassays for HCV antibodies in Gamimune N.
Schreiner C; Musmanno L; Kuenzi M; Torres J
Vox Sang; 1998; 74(3):156-60. PubMed ID: 9595642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
